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Abstract 
Mononuclear complexes of the type [Cu(valp)2(2,2-- 
bpy)]H20 (2), Cu(valp)z(phen) (3), and Cu(valp)z(dmph) 
(4), and polynuclear complexes of the type [Cu(valp)z(l~- 
4,4--bpy)I,, (5), and [Cuz(valp)4(~-4,4--bpy)I,, 66) 
[valp = valproate ion, bpy = bipyridine, phen = 1,10- 
phenanthroline, and dmph = 2,9-dimethyl-l,lO- 
phenanthroline], were synthesized and characterized by 
magnetic and spectroscopic measurements. Spectral and 
magnetic data f i r  complexes 2, 3, and 4 and the prelimi- 
nary x-ray measurements for complex 3 are consistent 
with mononuclear ~re .  The copper atom in 2 and 3 
is coordinated to two nitrogen atoms from diimine, two 
asymmetric arboxylic oxygen atoms from each of a 
bidentate valproate ions to give a tertragonally elongated 
CuN20 z + 02 chromophore. The copper atom in com- 
plex 4 is coordinated to two nitrogen atoms from dmph, 
two carboxylic oxygens of a bidentate valproate ion, and 
an oxygen atom of a monodentate carboxylic group of a 
second valproate ion to give a very distorted square 
pyramid or trigonal bipyramid CuN203 chromophore. 
The preceding data for 5 and 6 indicate that these 
complexes are polymeric in which the nitrogen atoms of 
4,4--bpy ligands bridge mononuclear Cu(valp) 2moities, 
coordinating equatorially in complex 5, while bridge 
binuclear Cu( l~-valp) 4Cu moities, coordinating axially 
in complex 6. The superoxide dismutase-mimetic activity 
of the binary complex, Cuz(valp) 4 (I), and of the previ- 
ous ternary complexes was measured and found to be in 
the order: 2 ~ 3 > 6 > 4 > 1 > 5. Journal of Inorganic 
Biochemistry 68, 167-175 (1997) © 1997 Elsevier Sci- 
ence Inc. 
Introduction 
The reactive superoxide free radical anion (O2) , which is 
a product of the oxygen metabolic ycle [i], was impli- 
cated in a wide range of clinical disorders. For example, it
is supposed to be implicated as a cause of tissue inflam- 
mation, aging, and some cancers [2]. Superoxide dismu- 
tases (SODs) are metalloenzymes that catalyze the dismu- 
tation of the superoxide anion to oxygen and hydrogen 
peroxide [Eq. (1)] and protect he living cells against he 
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toxicity of the superoxide anion [3], 
202 + 2H + SOD> 02 + H202 " (1) 
Hydrogen peroxide formed in this reaction is destroyed 
in vivo, for example, by catalase. One of these metalloen- 
zymes is Cu, Zn-SOD which is a dimeric protein (MW = 
31200) with two identical subunits, each containing one 
Cu 2 + and one Zn  2 + ion. The direct utilization of this 
natural enzyme as a pharmaceutical agent is limited be- 
cause of low membrane permeability as a consequence of
its high molecular weight [5]. So considerable fforts 
were made in order to obtain nontoxic, low molecular 
weight biomimetic molecules which are able to catalyze 
the dismutation of superoxide anion and therefore to 
provide a suitable alternative to superoxide dismutase in 
clinical application [6]. A variety of low molecular weight 
complexes of transition metals, especially those of copper, 
were prepared and studied as SOD mimics [4, 7, 8, 9]. 
Examples of such complexes include derivatives of antiin- 
flammatory drugs salicylates, amino acids, peptides, and 
amines [7, 8, 9]. 
Valproic acid (2-propylpentanoic acid) in the form of 
its sodium salt, (CH3CH2CH2)2CHCOO-Na ÷, has a 
wide spectrum of activity as an anticonvulsant drug [10]. 
The observation that copper(II) complexes of anticonvul- 
sant and antiinflammatory drugs are more active agents 
than the free drugs led to the suggestion that the activity 
of such drugs may be due to the in vivo formation of 
metallic complexes [11]. Physical studies of copper(II) 
valproate [12] have shown that it contains binuclear units 
with bridging carboxylate ligands similar to other 
copper(II) carboxylates [13]. Several binuclear copper(II) 
carboxylates of antiinflammatory drugs such as salicylates 
[8], indomethacin [14], and lonazolac [15] were studied as 
SOD mimics, but not of anticonvulsant drugs such as 
valproate. In addition, it was reported that the presence 
of coordination sites belonging to nitrogen heteroatomic 
rings such as imidazoles or pyridines is important for 
high SOD activity [16]. And since complexes with 
bipyridines and phenathrolines are DNA intercalators, 
showing an ability to inhibit nucleic acid synthesis in vivo 
[17], these ligands are used in this study to form ternary 
copper(II) valproate complexes. In addition, we examined 
the SODlike activity of these ternary complexes and of 
the binary binuclear copper(II) valproate complex and 
they are compared to the activity of the native SOD 
enzyme. 
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Experimental 
Reagents and Materials 
MI chemicals were of high purity grade (Aldrich or Sigma 
Chemical Co.) and were used without further purifica- 
tion. Tetrakis-lx-valproato dicopper(II), Cu2(valp) 4 (l), 
(valp = valproate ion) was prepared according to a pub- 
lished procedure [12] and recrystallized from absolute 
ethanol. 
Preparation of Complexes 
Bis(valFroato) (2,2' bipyridine) Copper(ll) monobydrate, 
[Cu(valp)z(2,2 -bpy]H20 , (2). A solution of 0.127 g (0.8 
mmol) of 2,2'-bipyridine in 20 ml methanol was added to 
0.283 g (0.4 mmol) of Cu2(valp) 4. The mixture was 
stirred at room temperature for 2 h. The blue solution 
was filtered and left in the hood to evaporate. The blue 
crystals that formed were recrystallized from chloroform 
and air dried. Anal. Calcd.: for C26H4oN205Cu: C, 
59.60; H, 7.64; N, 5.34. Found: C, 59.68; H, 7.56; N, 
5.38%. 
Bis(valproato)(1,10-pbenantbroline) copper(II), 
[Cu(valp)z(pben)], (3). A solution of 0.144 g (0.8 mmol) 
of 1,10-phenanthroline  20 ml methanol was added to 
0.280 g (0.4 mmol) of Cu2(valp) 4. The mixture was 
stirred at room temperature for 1.5 h. The blue solution 
was filtered and left in the hood to evaporate. The 
bluish-green crystals that formed were recrystallized from 
chloroform and air dried. Anal. Calcd.: for 
C28H38N204Cu: C, 63.45; H, 7.17; N, 5.29. Found: 
C, 63.57; H, 7.08; N, 5.35%. 
Bis(valproato) (2,9-dimethyl-1, I O-pbenantbroline) Cop- 
per(lI), [Cu(valp)2(dmph)l , (4). A solution of 0.156 g 
(0.75 mmol) of 2,9-dimethyl-l,10-phenanthroline in 25 
ml methanol was added dropwise to 0.258 g (0.37 mmol) 
of Cu2 (valp)4. The solution was protected from the light 
and stirred at room temperature for 2 h. The green 
solution was filtered and left in the hood to evaporate. 
The yellowish-green precipitate that formed was recrys- 
tallized from chloroform and air dried. Anal. Calcd.: for 
C30H42N204Cu: C, 64.57; H, 7.53; N, 5.02. Found: 
C, 63.96; H, 7,84; N, 5.01%. 
B is(valproato) (i z-4,4 --b ipyridin e) C opper(ID ,
[(Cu(valp)z(Iz-4,4--bpy)],, (5"). A solution of 0.116 g 
(0.74 mmol) of 4,4--bipyridine in 25 ml methanol was 
added to a solution of 0.269 g (0.37 mmol) of Cu2(valp) 4 
in 25 ml chloroform. The blue solution was stirred at 
room temperature for 2 h. The solution was filtered and 
left in the hood to evaporate. The purple precipitate that 
formed was recrystallized from (dimethylformamide) 
DMF-CH2CI2(I:3) and air dried. Anal. Calcd.: for 
C26H38N204Cu: C, 61.72; H, 7.52; N, 5.54. Found: C, 
61.91; H, 7.62; N, 5.32%. 
Tetrakis( Iz-valproato) ( i~-4, 4 --bipyridine) dicopper(ll), 
[Cu2(valp)4(~t-4,4 --bpy)] n(6). A solution of 0.58 g (0.37 
mmol) of 4,4--bipyridine in 20 ml methanol was added 
to a solution of 0.269 g (0.37 mmol) of Cu2(valp) 4 in 25 
ml chloroform. The bluish-green solution was stirred at 
room temperature for 2 h. The solution was filtered over 
an anhydrous diethylether and left in the hood to evapo- 
rate. The green precipitate that formed was recrystallized 
from chloroform and air dried. Anal. Calcd.: for 
C42H6808N2Cu2: C, 58.95; H, 7.95;.N, 3.27. Found: 
C, 58.91; H, 8.15; N, 3.15%. 
Physical Measurements 
Elemental analyses for C, H, and N were performed by 
Galbraith Laboratories, Knoxville, TN, U.S.A. Magnetic 
susceptibility measurements at 298 K of powdered sam- 
ples were determined by the Gouy method, with 
HgCo(NCS) 4 as a calibrant, and corrected for diamag- 
netism with appropriate Pascal constants. The effective 
magnetic moment was calculated from the expression: 
ix~ff = 2.84(xT)1/2. 
Infrared spectra of nujol or hexachlorobutadiene mulls 
sealed between polyethylene sheets were obtained in the 
4000 to 200 cm -I region with a Perkin-Elmer model 
843 infrared spectrophotometer. Electronic spectra of 
dichloromethane or methanol solutions were obtained 
with a Bausch and Lomb spectronic 2000. X-band elec- 
tron spin resonance (ESR) spectra of powdered samples 
and of methanol/toluene (or DMF/CHCI 3 (3:1) for 
complex (5") solutions at liquid nitrogen temperature 
were taken with a JEOL Jes-PE-1X spectrometer. 
Diphenylpicrylhydrazide (DPPH, g = 2.0036) was used 
as the calibrating field marker. 
Superoxide Dismutase Assay 
A standard assay method [8, 18] using alkaline dimethyl 
sulfoxide as a source of a superoxide generating system 
and nitro blue tetrazolium chloride (NBT) as a scavenger 
for superoxide was performed to measure the superoxide 
dismutase-mimetic activity of the copper(II) complexes. 
In a typical experiment 0.4 ml dimethyl sulfoxide 
(Me 2 SO) solution of a copper(II) complex to be assayed 
was added to a solution containing 2.1 ml of 0.2 M 
potassium phosphate buffer (pH 8.6) and 1 ml of 75 IxM 
NBT. The mixture was kept in ice for 15 min and then 
1.5 ml alkaline Me 2 SO solution (5raM NaOH and 0.55 
M deionized water) containing superoxide ions was added 
with stirring. The absorbance of the violet color devel- 
oped (diformazane formation) was monitored at 560 nm 
against asample prepared under similar conditions except 
that NaOH was absent in the Me2SO solution. The 
amount of copper complex which gives a 50% inhibition 
of NBT reduction was obtained from a plot of percent 
inhibition ver~ws complex concentration. 
Results and Discussion 
Magnetic and Spectroscopic Characterization 
The effective magnetic moments and electronic and IR 
spectral data are summarized in Table 1. The room 
temperature magnetic moments for complexes 2, 3, 4, 
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Table 1. Magnetic Moments and Electronic and IR Spectral Data for Cu(II) Valproate Complexes 
I~eff(BM) in CH3OH in CH2CI 2 
Compound (29810 (e =din 3 mol -I cm -1) (e =din 3 mo1-1 em -1) 
v~,~(CO2) 
-(efia- l) 
v~=,:(c02) 
-(6n- q 
Cu 2(valp)4, (1) 1.33 694(320) 671(410) 
375(146) 
Cu(valp)2(2,2 -bpy), (2) 1.90 670(60) 700(90) 
390(78) 
Cu(valp)2(phen), (3) 1.90 680(65) 700(90) 
400(74) 
Cu(valp)2(dmph) , (4) 1.95 750(75) 820(195) 
Cu(valp)2(4,4 -bpy), (5) 1.85 680 a 704(210) 
388(270) 
Cu 2(valp)4(4,4--bpy), (6  1.30 688 a 695(430) 
370(sh) b 383(270) 
1580 
1588 
1582 
1610 
1595 
1572 
1620 
1422 
1401 
1400 
1380 
1420 
1415 
1419 
'~ These complexes are not completely soluble in methanol and e values are not included. 
b sh = shoulder. 
and 5 are in the range 1.85-1.95 BM. These values are 
consistent with the presence of one unpaired electron in a 
mononuclear copper(II) complexes. The room tempera- 
cure magnetic moment for complex 6 is 1.30 BM. This 
subnormal value is lower than the spin-only magnetic 
moment of 1.73 BM, suggesting that coupling between 
copper(II) ions occurs. This value is comparable to the 
magnetic moment values of binuclear or polynuclear cop- 
per(II) carboxylate adducts of the type [Cu(RCOO) 2 L] 2 
[13], including those reported for binuchar copper(II) 
valproate adducts [19, 20]. 
The electronic spectra for complexes 2, 3, and Y 
obtained in methanol solutions exhibit one very broad 
absorption band in the 670-680 nm region (Table 1). 
This band is assigned to the copper(II) d-d transitions. 
The position of this band falls within the range expected 
for mononuchar copper(II) complexes that contain a 
CuS202 +O 2 chromophore in a distorted tetragonal 
geometry [20-22]. It is comparable to those found for 
mononuclear copper(II) valproate complexes with imida- 
zoles [21] which contain the trans- or cis-CuN202 + 02 
chromophore, including that for structurally known 
mononuclear copper(II) valproate with 2-methylim- 
idazole [21]. We recendy determined by single crystal 
x-ray structure analysis that this bis-adduct contains the 
trans-CuN20 2 + 0 2 chromophore in a tetragonal ar- 
rangement. The electronic spectra of these complexes in 
CHzC12 solutions exhibit a shift in the broad copper(II) 
d-d transitions to about 700 nm. In addition there is an 
additional band at 390 to 400 nm (Table 1), which 
appears to be of ligand-to-metal charge-transfer origin. A 
similar band (shoulder) around 400 nm with comparable 
molar absorptivity also attributed to charge transfer was 
previously observed for copper(II) carboxylate adducts 
[13, 23]. 
The electronic spectra of complex 4 display a very 
broad d-d band at 750 nm in methanol solution and 
shifted to about 820 nm in CH2C12 solution. It is similar 
to that seen for structurally known mononuclear 
[Cu(dmc)2(dmph)] (dmc = 2,5-diethoxycinnamic acid an- 
ion) [24] and other copper(II) carboxylates with dmph 
ligand [25, 26]. These complexes have rhombic structure, 
intermediate between square pyramidal and trigonal 
bipyramidal. The copper(II) ion is five coordinated, con- 
tains the CuN203 chromophore, and complexes by a 
chelating dmph, one bidentate and one monodentate 
carboxylate groups. The much lower energy of the d-d 
electronic transitions in this complex compared to the 
other diimine adducts indicates that the basal plane must 
be greatly distorted ue to steric congestion. 
The electronic spectrum of complex 6 in CH2CI 2 
solution exhibits two bands analogous to the spectra of 
other binuclear copper(II) adducts with bridging carbox- 
ylates [13, 19]. Band I at about 695 nm can be assigned to 
copper(II) d-d transitions, whereas band II at about 380 is 
referred to as a characteristic of the bridging system [13]. 
The positions of the bands are indeed comparable with 
those found for structurally known binuclear copper(H) 
valproate with pyridine [19]. 
The assignments of IR frequencies for the antisymmet- 
tic stretch, Pas, m(CO2), and the symmetric stretch, 
1,'~m(CO2) , of thZe valoroate group are ~iven in Table 1. 
F~r complexes 2, 3,'and Y~the Vasvm(C~O2) frequencies 
occur between 1572 and 1588 crfi -1, and v_~(CO 2) 
frequencies occur between 1400 and 1415 cm °e't. The 
band positions and the separation Av (Vasym(CO2) 
-V~m(CO)), between 157 and 188 cm -t, when com- 
pare'd with those of sodium valproate (llasvm(CO 2), 1570; 
Psym(CO2)), 1417; Av, 153 cm -1) are it{ the range ex- 
pected for carboxylate groups that act as asymmetrical 
bidentate ligands [21, 27]. These parameters are compara- 
ble to those reported for mononuchar copper(II) val- 
proate complexes that contain imidazoles having trans- or 
cis-eu~202 +02 chromophore, including the struc- 
turally known mononuclear Cu(valproate) 2. (2-methylim- 
idazole) 2 complex [21]. The stretching vibrations corre- 
sponding to those typical of coordinated 2,2--bpy (com- 
plex 2) occur at 740 and 770 cm -1, and those of 
phen(complex 3) occur at 730, 860, and 1510 cm -1 [28]. 
The stretching vibrations corresponding to the coordina- 
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tion mode of 4,4--bpy as bidentate bridging ligand in 
complex 5 occur at 1610, 1490, 1410(sh), 1225, 1080, 
1015, 830, 730, and 647 cm -1 These vibrations are 
comparable to those reported recently for the structurally 
known [CuX(4,4--bpy)]n(X = CI or Br) complexes in 
which 4,4=-bpy ligands bridge Cu(II) atoms [29]. A very 
broad band due to a water molecule was observed at 3440 
cm-1 in complex 2. When this complex was heated at 
II0°C for 10 to 15 rain this band only disappeared from 
the IR spectral while the rest of the spectrum retained its 
features. This observation indicated that the water 
molecule in this complex is not coordinated to the copper 
atom but is present as a lattice molecule which was lost 
on heating• 
The IR spectra for complex 4 exhibit two Vasym(CO 2) 
and two Vsym(CO 2 ) stretching bands (Table 1), indicating 
the presence of two valproate ligands involved in differ- 
ent coordination modes. The 1610 and 1380 cm- 1 (Av = 
230 cm -1) pair are assigned to the carboxyl group that 
acts as amonodentate ligand, and the 1595 and 1420 
cm -1 (shoulder) (Av = 175 cm -1) pair are assigned to 
the other carboxyl that acts as asymmetric bidentate 
ligand [27]. These results are consistent with the pro- 
posed mononuclear structure containing CuN203 chro- 
mophore. 
The IR stretching frequencies for 1)as, rn(CO 2) and 
• Y 
v s. re(CO2) of the valDroate groups m complex 6 occurred 
at' 1620 and 1419 cm -1, respectively. The positions of 
these frequencies and the separation between them (201 
cm- i ) when compared with those of sodium valproate (as 
shown previously); are in the range expected for the 
carboxylate group that acts as a bridging bidentate ligand 
[13a, 20, 26]. These parameters are comparable to those 
reported for the structurally known binuclear copper(II) 
valproate complex that contains pyridine [19]. The 
stretching vibrations corresponding to the coordination 
mode of 4,4--bpy as bidentate bridging ligand in this 
complex occur at 1610, 1490, 1220, 1070, 1010, 853,810, 
725, 655, and 630 cm -1. These vibrations are comparable 
with those reported recently for 4,4--bpy acting as biden- 
tate bridging ligand [29]. 
The ESR parameters, g and A, for frozen solutions 
and solid-state spectra of complexes under investigation 
are summarized in Table 2. The ESR spectra for frozen 
solutions of complexes 2, 3, and 5 exhibit resolved 
structure with gH > g± and are consistent with a tetrag- 
onally elongated structure [30]. A representative spectrum 
is that of 5 shown in Figure 1 (A). The g .  signal and the 
lowest field component of the gll signal exhibit 14N 
superhyperfine structure that consists of five equally 
spaced lines attributed to the presence of two nitrogen 
atoms in the copper(II) ion plane. ESR spectral parame- 
ters for these complexes are comparable to those previ- 
ously reported for tetragonally distorted copper(H) com- 
plexes that contain a CuN20 z + 02 chromophore, in- 
cluding those reported for copper(II) carboxylates with 
diimine [21-23, 30, 31]. In complexes for which struc- 
tural data are available, the copper(II) atom is bonded to 
two nitrogen donors and one oxygen atom from each of 
the two carboxylate ligands. The second oxygen atom of 
each carboxylate ligand is weakly bonded in a pseudo 
axial arrangement [21, 24, 25]. 
The room temperature ESR spectra of solid-state sam- 
ples of 2, 3 and 5 are anistropic and contain g.. and g ± 
components. The spectral data for these complexes are 
consistent with the presence of a tetragonally elongated 
CuN202 -~ 02 chromophore [21, 30]. Our preliminary 
x-ray data for complex 3 clearly indicated that in the 
solid state, Cu(II) atom is in a tetragonal co-ordination 
environment with in-plane bonds to two nitrogens form 
phenanthroline and one carboxylate oxygen atom from 
each of the two valproates with weaker off-axial bonds to 
other carbpxylate oxygens (Scheme I). The structure of 
this compound is similar to that determined recently for 
the mononuclear copper(II) complex of 3,5-diisopro- 
pylsalicylate with 1,10-phenanthroline [25]. Based on 
similar ESR spectral properties along with other spec- 
tral data for complexes 2 and 3, the structure of 2 can 
be described in the same manner except he 2,2'-bipyri- 
dine ligand replaced the 1,10-phenanthroline ligand 
(Scheme I). 
The g .  region of the solid-state ESR spectrum for 5 
is partially resolved into its x and y components and this 
may be attributed to slight distortion in the basal plane 
which contains a CuN202 chromophore. A similar spec- 
trum and spectral data are exhibited by the structurally 
known bis-adduct of copper(H) valproate with 2-methyl- 
imidazole [21]. In this complex the copper(II) ion is 
bonded to two imidazole nitrogen atoms and one oxygen 
atom from each of the two valproate ligands. The second 
oxygen atom of each valproate ligand is weakly bonded in 
a pseudo axial arrangement. The structure of the 
mononuclear units of complex 5 can be described in the 
same manner except hat two pyridine nitrogens of 4,4-- 
bipyridine bridging ligands replaced equatorially the two 
monodentate 2-methylimidazole igands and bridging 
Cu(valp) 2 moities (Scheme 1I). In addition, elemental 
analysis for this complex confirmed the formula 
[Cu(valp) 2(4,4--bpy)]. 
The solid-state and the frozen solution ESR spectra 
(Figure I(B)) of complex 4 are clearly of rhombic type 
(Table 2) suggesting a distortion form square symmetry. 
While the g~ and gy components exhibit copper(II) 
hyperfine structure, the gx component exhibits 14N su- 
perhyperfine structure consisting of five lines. This struc- 
ture is attributed to the presence of two nitrogen atoms 
coordinated to the copper(II) ion. The structure devia- 
tion from square symmetry is attributed to the presence 
of methyl groups in the 2 and 9 positions on the phenan- 
throline moiety, close to the coordinated nitrogens to 
copper(II). The ESR and other spectral parameters for 
this complex are comparable to those of ternary mononu- 
clear copper(II) carboxylate complexes with 2,9-dimethyl- 
1,10-phenanthroline, [24-26], including those reported 
for the structurally known copper(II) complex of 2,5-di- 
methoxycinnamic acid [24]. The geometry of these com- 
plexes was described as a very distorted square pyramid or 
a trigonal bipyramid. Accordingly, the copper(II) ion in 
complex 4 is five coordinated and complexes by two 
nitrogen atoms from dmph, two carboxylic oxygen atoms 
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Figure 1. Frozen-solution ESR spectra of 
compound 5 (A) and compound 4 (B). 
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Table 2. ESR Data for Cu(II) Valproate Complexes 
State A,ICu A N 
Compound (temperature) g~ g ± gll ( × 10~ cm-  I ) (× 104~cm - l) 
Cu2(valp)4, (1) b Solid (room) 2.130 2.016 2.341 -- --  
(D = 0.344 cm- l) 
Cu(valp)2(2,2 --bpy), (2) Solid (room) 2.144 2.080 2.273 -- --  
Frozen (77 K) 2.130 2.069 2.270 170 14.5 
Cu(valp)2(phen), (3) Solid (room) 2.151 2.090 2.273 -- --  
Frozen (77K) 2.135 2.065 2.277 170 14.5 
Cu(valp)e(dmph), (4) Solid (room) 2.176 gx = 2.089 gz = 2.308 -- --  
gyx= 2.132 
Frozen (77 K) 2.178 = 2.073 gz = 2.324 A x = 18.8 12.0 
gy = 2.137 Ay = 55.4 
A= = 130 
Solid (room) 2.120 gx = 2.055 2.230 --  --  
g. = 2.075 
Frozen (77 K) 2.131 Y2.062 2.270 165 14.0 
(A,!N = 10.0) 
Solid (room) 2.147 2.041 2.360 --  --  
(D = 0.369 cm l) 
Cu(valp)2 (~-4,4--bpy), ($) 
Cu 2 (valp)4(p~-4,4--bpy), (6) 
a I go Values are calculated from go = T(2g± +gll ). 
ESR data re taken from Ref. 19. 
of a bidentate valproate, and one oxygen atom of a 
monodentate carboxyl group of a second valproate 
molecule (Scheme III). 
Solid-state ESR spectrum of complex 6 at room tem- 
perature exhibits three transitions: a moderately strong 
absorption at 500 G, a weak absorption at 6188 G (paral- 
lel Hzl ,  and Hz2 components, respectively), and a strong 
absorption at 4854 G (perpendicular component H l). 
Using these absorptions typical for the randomly oriented 
triplet state (S = 1) of axial symmetry and the available 
literature methods [13a, 22], the ESR parameters for this 
complex are calculated (Table 2). The parameters .gll, 
g • ,  and D values along with other spectral properties 
are comparable to those reported for other binuclear or 
polynuclear copper(II) carboxylate adducts with nitrogen 
donor ligands [13, 19, 20, 22], including those reported 
for the structurally known binuclear copper(II) valproate 
adduct with pyridine [19]. On these bases the formulation 
[Cu2(valp)4(l~-4,4--bpy] . can be proposed for the binary 
complex 6, in which 4,4 -bipyridine molecules bridge 
binuclear CuQx-valp)4Cu moities, coordinating axially 
(Scheme IV). In addition, elemental analysis for this 
complex confirmed the formula [Cu2(valp)4(4,4--bpy)]. 
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Superoxide Dismutase-Mimet ic  Activity 
The superoxide dismutase-mimetic activity of the binary 
Cu2(valp) 4 complex and their ternary complexes with 
diimines was measured using the alkaline Me 2 SO-NBT 
method [8, 18]. A unit superoxide dismuatase activity is 
the concentration of complex or enzyme which causes 
50% inhibition of alkaline Me 2 SO mediated reduction of 
NBT; this concentration is termed ICs0 for comparative 
purposes. One representative example of a plot of percent 
inhibition with increase in concentration is that of com- 
plex 2 shown in Figure 2. The data for SOD mimetic 
activity of the complexes under investigation are given in 
Table 3. In addition, to ascertain the effectiveness of the 
present complexes as functional SOD mimics, we com- 
pared the IC50 of several known Cu(II) complexes (Table 
3), which were previously demonstrated as SOD mimics 
[8], by the NBT method under the same conditions. The 
data suggest hat the activities of the present complexes 
are higher than those of other copper(II) complexes. 
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The mechanism believed to be operating in both Cu, 
Zn-SOD and Cu(II) complexes involves the initial bind- 
ing of superoxide to the axial Cu(II) site, with subsequent 
redox cycling of the Cu(II) ion [4, 32], 
CU2++ O2---> Cu++ 02, (2) 
Cu++ 02+ 2H +---> Cu2++ H20 z . (3) 
Some factors were proposed which may discriminate 
among the dismutation features of the copper(II) com- 
plexes in vitro, and these may include: (1) A fast exchange 
of molecules axially linked to the center and limited steric 
hindrance to the approach of the superoxide anion are 
considered essential requirements for the successful bind- 
ing of the O~ radical [33]. (2) The flexibility of the 
copper(II) arrangement, which facilitates the interaction 
of the 02 radical, followed by the rapid electron transfer 
reaction which results in reduction to copper(I) species 
[34]. (3) The favorable response of av-electrons of the 
coordinated ligands in stabilizing the Cu(II)-O~ interac- 
tion [7e, f, 8b]. These requirements are satisfied in the 
tetragonally distorted complexes 2, 3, and Y and in the 
--L L 
O O 
l Cu Cu L L 
/ \o o / \ 
R R 
RCOO = Valproate anion; L L = 4,4'-bpy 
Scheme IV 
distorted square pyramid or trigonal bipyramid complex 
4. In these complexes which contain the CuN202 + 02 
chromophore (in complexes 2, 3 and 5) or the CuNzO 3 
chromophore (in complex 4), the axial atoms are the 
weakly coordinated second carboxylate oxygen atoms. 
The weakly interacting oxygen atoms are readily dissoci- 
ated to provide sites on Cu(II) for O/  bonding. Dissocia- 
tion of the weakly bonding donors would also facilitate 
any necessary geometrical changes induced by 02 bond- 
ing. The SOD-like activity of the binary binuclear com- 
plex 1 is explained in terms of both a fast exchange of 
axial solvent molecules and a limited steric hindrance to 
the approach of the superoxide anion in the complex. 
Polynuclear complex 6 is likely to dissociate in solution 
into its binuclear units [Cu2(valp)4(4,4--bpy)]. The rela- 
tively high catalytic activity of this complex may be due 
to axial coordination of the 4,4--bpy ligand on one 
Cu(II) atom which activates the axial site of the other 
Cu(II) atom for O~- bonding and further stabilizes this 
interaction through d-Tr interaction between the 
copper(II) and the "rr-system of the 4,4--bpy ligand. 
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Figure 2. A plot of percentage ofinhibiting NBT reduction with an increase in the concentration f compound 2. 
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Table 3. Superoxide Dismutase-Mimetic Actvity 
Compound IC]o / tiM 
Cu2(valp)4, (1) 
[Cu(valp)2(2,2--bpy)], H20, (2) 
Cu(valp)2(phen), (3) 
Cu(valp)2(dmph), (4) 
[Cu(valp)2(l~-4,4--bpy)] n, (5) 
[Cu 2(valp)4(l~-4,4--bpy)]~, (6) 
Cu(salicylate)2 ° 
. . . .  b Cu(asplrlnate)2(pyndme) 2 
Cu(glycylglycinate)(2,2--bpy), 3H2Oc 
Cu(glycylglycinate)(phen), 3H20 c 
Cu(cimetidine)2(CIO4)2 d 
Cu,Zn-SOD 
10.4 
4.2 
4.5 
6.3 
18.3 
5.0 
44 
13 
25 
32 
4.0 
0.72 
ICs0 is defined as the concentration f complex or enzyme which 
produces 50% inhibition of NBT reduction. 
b Ref. 8a. 
Ref. 8b. 
a SODlike activity was determined bythe xanthine-xanthine oxidase 
system as described inRef. 7b. 
In conclusion, the SODlike activity of binary and 
ternary copper(II) complexes of the anticonvulsant drug 
valproate with diimines is relatively lower than the activ- 
ity of the native SOD enzyme (Table 3). The ICs0 values 
measured for the most active ternary complexes 2, 3, and 
6 are among the highest available in the literature for 
copper(II) complexes showing SOD-mimetic activity 
studied under similar conditions [8], and are only about 
six times lower than that determined for the native en- 
zyme on a molar basis by the NBT method [8]. On the 
other hand, the least active adduct 5 is about 25 times 
less active than the native enzyme on a molar basis. 
These complexes are potent SOD mimics, especially the 
most active ones, considering the very low molecular 
weights of these complexes when compared to that of the 
native SOD enzyme. 
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